A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer
KN Moore, TJ Herzog, S Lewin, RL Giuntoli… - Gynecologic …, 2007 - Elsevier
OBJECTIVE.: Cisplatin-based combination therapy produces higher response rates and
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer
KN Moore, TJ Herzog, S Lewin… - Gynecologic …, 2007 - gynecologiconcology-online.net
Objective. Cisplatin-based combination therapy produces higher response rates and
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
KN Moore, TJ Herzog, S Lewin, RL Giuntoli… - Gynecologic …, 2007 - europepmc.org
Objective Cisplatin-based combination therapy produces higher response rates and
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …
[引用][C] A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer
M KN - Gynecol Oncol, 2007 - cir.nii.ac.jp
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or
persistent cervical cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
persistent cervical cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer
KN Moore, TJ Herzog, S Lewin… - Gynecologic …, 2007 - jhu.pure.elsevier.com
Objective.: Cisplatin-based combination therapy produces higher response rates and
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer
KN Moore, TJ Herzog, S Lewin, RL Giuntoli… - Gynecologic …, 2007 - infona.pl
Cisplatin-based combination therapy produces higher response rates and improved
survival, in comparison to single-agent cisplatin in the treatment of cervical cancer. Cisplatin …
survival, in comparison to single-agent cisplatin in the treatment of cervical cancer. Cisplatin …
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer
KN Moore, TJ Herzog, S Lewin… - Gynecologic …, 2007 - pubmed.ncbi.nlm.nih.gov
Objective Cisplatin-based combination therapy produces higher response rates and
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer
KN Moore, TJ Herzog, S Lewin… - Gynecologic …, 2007 - pure.johnshopkins.edu
Objective.: Cisplatin-based combination therapy produces higher response rates and
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …
[引用][C] A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer
M KN - Gynecol Oncol, 2007 - cir.nii.ac.jp